Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$76 Mln
P/E Ratio
--
P/B Ratio
0.79
Industry P/E
--
Debt to Equity
0
ROE
-0.5 %
ROCE
-49.79 %
Div. Yield
0 %
Book Value
1.64
EPS
-0.46
CFO
$-100.18 Mln
EBITDA
$-54.70 Mln
Net Profit
$-108.81 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Context Therapeutics Inc (CNTX)
| -10.12 | 22.27 | 0.63 | -30.61 | -16.48 | -67.34 | -- |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Context Therapeutics Inc (CNTX)
| -7.02 | 73.39 | -75.49 | -98.77 | -35.50 | 16,800.00 | -99.56 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.78 | 9,808.03 | 20.22 | 23.13 | |
| 290.25 | 8,956.09 | 22.08 | 58.42 | |
| 26.54 | 9,559.25 | -- | -28.77 | |
| 103.22 | 10,030.35 | 30.81 | 14.16 |
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated... lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania. Address: 2001 Market Street, Philadelphia, PA, United States, 19103 Read more
Co-Founder, President, CEO & Director
Mr. Martin A. Lehr
Co-Founder, President, CEO & Director
Mr. Martin A. Lehr
Headquarters
Philadelphia, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Context Therapeutics Inc (CNTX) stood at $ 98 Mln as on 31-Dec-24
The share price of Context Therapeutics Inc (CNTX) is $1.00 (NASDAQ) as of 23-Apr-2025 16:00 EDT. Context Therapeutics Inc (CNTX) has given a return of -16.48% in the last 3 years.
Context Therapeutics Inc (CNTX) has a market capitalisation of $ 76 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Context Therapeutics Inc (CNTX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Context Therapeutics Inc (CNTX) and enter the required number of quantities and click on buy to purchase the shares of Context Therapeutics Inc (CNTX).
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania. Address: 2001 Market Street, Philadelphia, PA, United States, 19103
The CEO & director of Mr. Martin A. Lehr. is Context Therapeutics Inc (CNTX), and CFO & Sr. VP is Mr. Martin A. Lehr.
There is no promoter pledging in Context Therapeutics Inc (CNTX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Context Therapeutics Inc (CNTX) | Ratios |
|---|---|
|
Return on equity(%)
|
-49.89
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Context Therapeutics Inc (CNTX) was $0 Mln.
$0.06
(
